Publication date: Jul 19, 2024

Early in the coronavirus disease 2019 (COVID-19) pandemic, a low incidence of cardiovascular complications was reported in Singapore. Little was known about the trend of cardiovascular complications as the pandemic progressed. In this study, we examined the evolving trends in electrocardiographic and cardiovascular manifestations in patients hospitalised with COVID-19. We examined the first 1781 consecutive hospitalised patients with polymerase chain reaction-confirmed COVID-19. We divided the population based on whether they had abnormal heart rate (HR) or electrocardiography (ECG) or normal HR and ECG, comparing the baseline characteristics and outcomes. Cardiovascular complications were defined as acute myocardial infarction, stroke, pulmonary embolism, myocarditis and mortality. The 253 (14. 2%) patients who had abnormal HR/ECG at presentation were more likely to be symptomatic. Sinus tachycardia was commonly observed. Troponin I levels (97. 0 +/- 482. 9 vs. 19. 7 +/- 68. 4 ng/L, P = 0. 047) and C-reactive protein levels (20. 1 +/- 50. 7 vs. 13. 9 +/- 24. 1 μmol/L, P = 0. 003) were significantly higher among those with abnormal HR/ECGs, with a higher prevalence of myocarditis (2. 0% vs. 0. 5%, P = 0. 019), pulmonary embolism (2. 0% vs. 0. 3%, P = 0. 008) and acute myocardial infarction (1. 2% vs. 0. 1%, P = 0. 023). After adjusting for age and comorbidities, abnormal HR/ECG (adjusted odds ratio 4. 41, 95% confidence interval 2. 21-8. 77; P < 0. 001) remained independently associated with adverse cardiovascular complications. Over time, there was a trend towards a higher proportion of hospitalised patients with cardiovascular complications. Cardiovascular complications appear to be increasing in proportion over time among hospitalised patients with COVID-19. A baseline ECG and HR measurement may be helpful for predicting these complications.

Semantics

Original Article